(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX), an integrated essential medicines company, announced Wednesday that it has received Abbreviated New Drug Application or ANDA approval from the U.S.
MUMBAI, India and WARREN, N.J., Nov. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and its wholly owned subsidiary Cipla USA Inc. (hereafter referred to as 'Cipla'), today ...
CHICAGO, June 07, 2019 (GLOBE NEWSWIRE) -- Tolmar Pharmaceuticals Inc., a fully integrated specialty pharmaceutical company, today announced new formulary placement for ELIGARD ® with Rite-Aid’s ...
Please provide your email address to receive an email when new articles are posted on . A subcutaneous injection of leuprolide acetate every 6 months was effective and well tolerated in treating ...
Combined mTOR and AKT inhibition in renal cell carcinoma (RCC). Background: Leuprolide acetate is a synthetic analog of gonadotropin hormone-releasing hormone (GnRH-a) that reduces serum testosterone ...
The Food and Drug Administration has cleared Amneal’s leuprolide acetate for injection, which is indicated in the palliative treatment of advanced prostatic cancer. “We are making tremendous progress ...
The 6-month subcutaneously injectable leuprolide acetate (Fensolvi, Tolmar Pharmaceuticals) effectively and safely treats children with central precocious (early) puberty, research suggests. Findings ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results